Navigation Links
Cannabis Science Announces Corporate Changes, Appointing Raymond Dabney As President And CEO And Dr. Dorothy Bray As Scientific Advisory Board Chair And Clinical Development Consultant

COLORADO SPRINGS, Colo., Nov. 6, 2014 /PRNewswire/ -- Cannabis Science, Inc. (OTC: CBIS), a U.S. Company specializing in cannabis formulation-based drug development and related consulting, is pleased to announce that some major corporate changes are taking place, allowing the Company to better position itself to face the continuing evolution of the industry and ongoing and incoming projects and initiatives.

Mr. Raymond C. Dabney, co-founder of the Company will become Director, President and CEO, overseeing day-to-day operations. Mr. Dabney previously served as a management consultant for the Company working closely with Dr. Dorothy Bray and the Company's board of directors.

Mr. Dabney is no stranger to great transformation and brings over 25 years of experience in corporate finance, communications, management, sales and marketing. Mr. Dabney has played a lead role in the financing, business development, and public relations programs for several public and private companies. Mr. Dabney's niche market knowledge, team leadership, and management style facilitate growth and forward thinking that successfully brings his projects from concept to completion.

Dr. Bray who is ImmunoClin Corporation's Founder, President and CEO will continue working closely with Cannabis Science. The two companies have recently signed a collaboration agreement in which ImmunoClin Corporation (OTC: IMCL) will provide laboratory facilities and services to support a ground breaking joint research project between Cannabis Science and Unistraw Holdings Pce Ltd. of Singapore with operations in India to develop cannabis and cannabinoid-based novel formulations. Dr. Bray will focus on the Company's drug research and development as Clinical Development Consultant and Chair of the Cannabis Science Scientific Advisory Board. She will also be involved in the Michigan cannabis initiative working with Michigan Green Technologies LLC (MGT), a Cannabis Science affiliate, and contribute to several of Cannabis Science's European projects and initiatives, including ongoing development of cannabinoid-based formulation for neurological disorders. "I am delighted to be able to hand over the leadership of Cannabis Science to Mr. Dabney, allowing me to focus on scientific research and the challenge of bringing novel products to market during this rapidly evolving era in the cannabis industry that we are facing today," commented Dr. Bray.

Additionally, going forward, Mr. Dabney will be creating specific drug development teams with Dr. Bray and the Scientific Advisory Board to target particular projects and accelerate the research and development process. These particular teams will be headed by some of the leading experts, including Dr. Roscoe Moore, Special Senior Advisor to the company and retired US Assistant Surgeon General; Mario Lap, Director of European Operations for Cannabis Science, along with other key leaders to be announced with their new positions and responsibilities.

Along with these managerial changes, Cannabis Science has revised its website to make it more user friendly and provide new proactive information sharing and processes. The new website includes a beta version of the Patient Access Center (PAC). The PAC, is a social network that will allow current and former patients, caregivers, doctors and investors to login, share, and update relevant and pertinent data on medical cannabis, as well as personal experiences, anecdotes, answers to questions, and the like. Visitors will also be able to contact the company directly.

About Cannabis Science, Inc.

Cannabis Science, Inc., takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. Cannabinoids have an extensive history dating back thousands of years, and currently, there are a growing number of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness. Our initial focus is on skin cancers and neurological conditions.

Forward-Looking Statements

This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing words such as "anticipate," "seek," "intend," "believe," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc., does not undertake any duty nor does it intend to update the results of these forward-looking statements.

Cannabis Science, Inc.
Raymond C. Dabney, President and CEO
Tel: 1.310.650.3788

Dr. Dorothy Bray, Scientific Advisory Board Chair
Tel: 1.888.777.0658

Investment Inquiries
Robert Kane, CFO & Director
Tel: 1.561.420.4824


SOURCE Cannabis Science, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Rapid Fire Marketing: CANNAcig to Sponsor Medical Cannabis Cup 2012 in San Francisco
2. Cannabis Science Gets Set to Release "Phytiva" Its Newest Brand of Over-the-Counter Skin and Nutraceutical Product Lines Through its Newest Venture Phytiva Pharmaceuticals Inc.
3. Cannabis Science Provides Corporate Guidance on Preclinical Initiatives and Recent Corporate Developments for its Shareholders; CBIS Announces plans for 1st Q of 2013 Webinar Investor Call
4. Beth Israel Deaconess Medical Center, Harvard Medical School Study Confirms Cannabis Sciences Approach to Development of CS-TATI-1 to Inhibit Kaposi Sarcoma
5. New Study Shows Cannabis Effects on Driving Skills
6. Optimism of Cannabis Patients Creates More Demand for Phytiva Brand of Cannabinoid Solutions as Illinois and New Hampshire Take Key Legislative Steps Toward Legalization of Medical Cannabis
7. Abattis Provides $10,000 Sponsorship to the American Herbal Pharmacopoeia for Cannabis Monograph Project
8. Cannabis Science announces preclinical development program for CS-TATI-I, commencing EU operations in the Netherlands and sourcing proprietary material for pharmacokinetic characterization
9. Virogen Announces Launch of New Business Unit, "The Cannabis Connection", and Sets Sights on $15-20 Billion Legal Marijuana Market
10. Virogens New Business Unit, "The Cannabis Connection," to Focus on High-End Medicinal Marijuana Dispensary Niche within $15-20 Billion Legal Marijuana Market
11. Cannabis Science Appoints Clinical Development Expert, Dr. Dorothy Bray, as Chief Executive Officer (CEO) and Director, Focusing on CS-TATI-1 and Building Companys Drug Development Pipeline
Post Your Comments:
(Date:10/8/2019)... (PRWEB) , ... October 08, 2019 , ... ... and manufacturing solutions for drugs, biologics, gene therapies, and consumer health products, today ... Mandalay Bay Resort & Casino, Las Vegas on Oct. 15 – 19, 2019. ...
(Date:10/8/2019)... ... October 08, 2019 , ... ... announced that FocalPoint Holdings, a privately-held investment and management firm specializing in ... than 8,000 ophthalmology and optometry providers Luma Health’s patient relationship technology to ...
(Date:10/8/2019)... ... ... ChoiceSpine LLC, a privately-held spinal device manufacturer based in Knoxville, TN, today announced ... and drive sales growth. , The following changes and new additions have been made ... to Senior Vice President of Strategic Partnerships; , Keith Clements hired ...
Breaking Medicine Technology:
(Date:10/8/2019)... ... 08, 2019 , ... What unique insights can three former Surgeons General of ... in the nation? That question will be answered at ICAA 2019: Shaping the Future ... The event will take place October 10-12, 2019, at the Gaylord Palms Resort and ...
(Date:10/8/2019)... ... October 08, 2019 , ... Dr. Amir HagShenas of Silicon Valley Smile Solutions ... relief from this common and treatable condition. Dr. HagShenas’ goal is to treat ... with uncomfortable symptoms, including tender and bleeding gums, and to prevent gum disease from ...
(Date:10/8/2019)... ... 08, 2019 , ... As a world-renowned expert using intravital ... with the University of Maryland Department of Veterinary Medicine, continues to make new ... and his lab have discovered a new pathway by which liver macrophages called ...
(Date:10/8/2019)... ... October 08, 2019 , ... ... and pathologists, 4medica® President Gregg Church will inform conference attendees how ... reinventing labs orders management-by starting with the right, clean patient data. The single ...
(Date:10/8/2019)... ... October 08, 2019 , ... The University of California ... Health Awards 1st Round (Top Ten) Finalist in its Best Cardiovascular Digital Diagnostic ... that promote faster, better, more cost-effective healthcare by improving outcomes such as shorter ...
Breaking Medicine News(10 mins):